EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are considered the standard, first-line therapy for advanced or metastatic non-small cell lung cancer (NSCLC) harboring sensitizing EGFR mutations [1].